PharmaResearch Co Ltd
KOSDAQ:214450
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fabrinet
NYSE:FN
|
KY |
PharmaResearch Co Ltd
Operating Income
PharmaResearch Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Operating Income
₩214.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
45%
|
CAGR 10-Years
30%
|
|
|
Celltrion Inc
KRX:068270
|
Operating Income
₩1.2T
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Operating Income
-₩30B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Operating Income
-₩36.3B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Income
₩106.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
300%
|
CAGR 10-Years
97%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Income
-₩40.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
PharmaResearch Co Ltd
Glance View
In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.
See Also
What is PharmaResearch Co Ltd's Operating Income?
Operating Income
214.4B
KRW
Based on the financial report for Dec 31, 2025, PharmaResearch Co Ltd's Operating Income amounts to 214.4B KRW.
What is PharmaResearch Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
30%
Over the last year, the Operating Income growth was 70%. The average annual Operating Income growth rates for PharmaResearch Co Ltd have been 48% over the past three years , 45% over the past five years , and 30% over the past ten years .